Prolonged humoral and cellular immunity in COVID-19-recovered patients

Brodin, 2021, Immune determinants of COVID-19 disease presentation and severity, Nat. Med., 27, 28, 10.1038/s41591-020-01202-8 Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J. Clin. Invest., 130, 2620, 10.1172/JCI137244 Diao, 2020, Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19), Front. Immunol., 11, 827, 10.3389/fimmu.2020.00827 Folegatti, 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet, 396, 467, 10.1016/S0140-6736(20)31604-4 Grifoni, 2020, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell, 181, 1489, 10.1016/j.cell.2020.05.015 Hashem, 2020, Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients, Viruses, 12, 10.3390/v12121390 Henry, 2020, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clin. Chem. Lab. Med., 58, 1021, 10.1515/cclm-2020-0369 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Iyer, 2020, Dynamics and significance of the antibody response to SARS-CoV-2 infection, medRxiv Jacob, 2020, On the genetics and immunopathogenesis of COVID-19, Clin. Immunol., 220, 10.1016/j.clim.2020.108591 Juno, 2020, Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19, Nat. Med., 26, 1428, 10.1038/s41591-020-0995-0 Lin, 2020, Long-term infection of SARS-CoV-2 changed the body's immune status, Clin. Immunol., 218, 10.1016/j.clim.2020.108524 Liu, 2020, Decreased T cell populations contribute to the increased severity of COVID-19, Clin. Chim. Acta, 508, 110, 10.1016/j.cca.2020.05.019 Lou, 2020, Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset, Eur. Respir. J., 56, 10.1183/13993003.00763-2020 Mahallawi, 2020, Case Report: A recovered SARS CoV-2 patient protected from reinfection, Front. Med. (Lausanne), 7 Mahallawi, 2021, A serological assay to detect human SARS-CoV-2 antibodies, J. Taibah Univ. Medical Sci., 16, 57 Maucourant, 2020, Natural killer cell immunotypes related to COVID-19 disease severity, Sci. Immunol., 5, 10.1126/sciimmunol.abd6832 MOH, 2020. Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19. Version 2.2. Retrieved from https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf. Peng, 2020, Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19, Nat. Immunol., 21, 1336, 10.1038/s41590-020-0782-6 Phillip Ruiz, M., Michael J. Borowitz, Henok Tilahun, T.C., Liz Keyer, & Coxey, A., 2007. Productivity and Efficiency of 6-Color BD Multitest and BD Trucount Technologies. Robbiani, 2020, Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Nature, 584, 437, 10.1038/s41586-020-2456-9 Tan, 2020, Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduct Target Ther, 5, 33, 10.1038/s41392-020-0148-4 Wang, 2020, Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia, J. Infect. Dis., 221, 1762, 10.1093/infdis/jiaa150 WHO, 2020. Draft landscape of COVID-19 candidate vaccines. Retrieved from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Xu, 2020, Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster, Emerg Microbes Infect, 9, 924, 10.1080/22221751.2020.1752610 Yang, 2020, Immune characteristics of severe and critical COVID-19 patients, Signal Transduct Target Ther., 5, 179, 10.1038/s41392-020-00296-3 Yu, 2020, DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science, 369, 806, 10.1126/science.abc6284 Zheng, 2020, Functional exhaustion of antiviral lymphocytes in COVID-19 patients, Cell. Mol. Immunol., 17, 533, 10.1038/s41423-020-0402-2 Zhu, 2020, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, Lancet, 395, 1845, 10.1016/S0140-6736(20)31208-3